









市场行情
/
股票
/
nasdaq-vrca
/

Verrica Pharmaceuticals Inc

VRCA

7.820USD

-0.290-3.58%

收盘 12/19, 16:00（美东）报价延迟15分钟

74.21M总市值

亏损市盈率 TTM



Verrica Pharmaceuticals Inc

7.820

-0.290-3.58%

概览公司财务分析

概览

公司

财务

分析

关于 Verrica Pharmaceuticals Inc 公司

Verrica Pharmaceuticals Inc. is a dermatology therapeutics company developing and selling medications for skin diseases requiring medical intervention. The Company's product portfolio consists of one approved product with several potential follow-on indications, as well as an additional pipeline product. Its commercial product, YCANTH (VP-102), is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin. YCANTH (VP-102) is being developed for the treatment of molluscum contagiosum in adult and pediatric patients two years of age and older. It is also engaged in developing YCANTH (VP-102) for a potential follow-on indication for the treatment of common warts. Its second development candidate, VP-315, is an oncolytic peptide-based injectable therapy for the potential treatment of dermatology oncologic conditions, including basal cell carcinoma (BCC).

Verrica Pharmaceuticals Inc简介



公司代码VRCA

公司名称Verrica Pharmaceuticals Inc

上市日期Jun 15, 2018

CEORieger (Jayson)

员工数量71

证券类型Ordinary Share

年结日Jun 15

公司地址44 West Gay Street

城市WEST CHESTER

上市交易所NASDAQ OMX - NASDAQ BASIC

国家United States of America

邮编19380

电话14844533300

网址https://verrica.com/

公司代码VRCA

上市日期Jun 15, 2018

CEORieger (Jayson)

Verrica Pharmaceuticals Inc公司高管



名称

名称/职务

职务

持股

持股变动

Dr. Jayson Rieger

President, Chief Executive Officer, Director

183.30K

+105.98%

Mr. David Zawitz

Chief Operating Officer

21.00K

+90.91%

Dr. Noah L. Rosenberg, M.D.

Chief Medical Officer

2.36K

Dr. Diem Nguyen, Ph.D.

Independent Director

10.00

Dr. Gavin Corcoran

Independent Director

2.00

Dr. Lawrence Eichenfield, M.D.

Independent Director

Mr. John J. Kirby

Interim Chief Financial Officer, Interim Principal Financial Officer

Mr. Paul B. Manning

Chairman of the Board

Mr. Mark A. Prygocki, Sr.

Independent Director

名称

名称/职务

职务

持股

持股变动

Dr. Jayson Rieger

President, Chief Executive Officer, Director

183.30K

+105.98%

Mr. David Zawitz

Chief Operating Officer

21.00K

+90.91%

Dr. Noah L. Rosenberg, M.D.

Chief Medical Officer

2.36K

Dr. Diem Nguyen, Ph.D.

Independent Director

10.00

Dr. Gavin Corcoran

Independent Director

2.00

Dr. Lawrence Eichenfield, M.D.

Independent Director

收入明细

由于公司未披露，未能获取相关数据

由于公司未披露，未能获取相关数据

业务

地区

由于公司未披露，未能获取相关数据

股东统计

更新时间: 12月5日周五

持股股东

股东类型

持股股东

占比

Manning (Paul B.)

28.51%

BKB Growth Investments LLC

20.94%

Caligan Partners, LP

5.78%

Affinity Asset Advisors LLC

4.42%

Armistice Capital LLC

4.00%

其他

36.35%

持股股东

占比

Manning (Paul B.)

28.51%

BKB Growth Investments LLC

20.94%

Caligan Partners, LP

5.78%

Affinity Asset Advisors LLC

4.42%

Armistice Capital LLC

4.00%

其他

36.35%

股东类型

持股股东

占比

Individual Investor

31.41%

Corporation

21.10%

Hedge Fund

14.84%

Investment Advisor

2.60%

Investment Advisor/Hedge Fund

2.43%

Venture Capital

0.18%

Research Firm

0.02%

其他

27.43%

机构持股



更新时间: 10月1日周三

报告期

机构数

持股数

持股占比

持股变动

2025Q3

171

2.46M

26.06%

-1.46M

2025Q2

183

8.91M

96.35%

+3.15M

2025Q1

194

69.94M

75.99%

+19.16M

2024Q4

191

70.39M

77.72%

+35.42M

2024Q3

179

29.67M

67.28%

-5.27M

2024Q2

173

33.68M

79.75%

-1.13M

2024Q1

171

34.51M

82.01%

-2.46M

2023Q4

170

35.04M

83.66%

+1.56M

2023Q3

172

32.74M

78.91%

-2.85M

2023Q2

169

31.35M

77.69%

+2.98M

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

Manning (Paul B.)

4.98M

52.73%

+3.12M

+167.58%

Nov 26, 2024

BKB Growth Investments LLC

597.61K

6.33%

+597.61K

Nov 22, 2024

Caligan Partners, LP

923.91K

9.78%

+24.62K

+2.74%

Jun 30, 2025

Armistice Capital LLC

888.13K

9.4%

+31.39K

+3.66%

Jun 30, 2025

The Vanguard Group, Inc.

216.83K

2.3%

-19.30K

-8.17%

Jun 30, 2025

Stalfort (John A)

187.38K

1.98%

+23.81K

+14.56%

Apr 01, 2025

Rieger (Jayson)

88.99K

0.94%

+30.02K

+50.90%

Apr 01, 2025

Sovran Advisors LLC

75.04K

0.79%

+35.82K

+91.35%

Jun 30, 2025

持股ETF



更新时间: 12月6日周六

机构名称

占比

iShares Micro-Cap ETF

iShares Russell 2000 Growth ETF

Goldman Sachs ActiveBeta US Small Cap Equity ETF

Dimensional US Core Equity 1 ETF

Global X Russell 2000 Covered Call ETF

Invesco Dorsey Wright SmallCap Momentum ETF

Avantis US Small Cap Equity ETF

ProShares UltraPro Russell2000

Global X Russell 2000 ETF

iShares Russell 2000 ETF

iShares Micro-Cap ETF

占比0%

iShares Russell 2000 Growth ETF

占比0%

Goldman Sachs ActiveBeta US Small Cap Equity ETF

占比0%

Dimensional US Core Equity 1 ETF

占比0%

Global X Russell 2000 Covered Call ETF

占比0%

Invesco Dorsey Wright SmallCap Momentum ETF

占比0%

Avantis US Small Cap Equity ETF

占比0%

ProShares UltraPro Russell2000

占比0%

Global X Russell 2000 ETF

占比0%

iShares Russell 2000 ETF

占比0%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

类型

比率

Jul 23, 2025

Merger

10→1

公告日期

类型

比率

Jul 23, 2025

Merger

10→1

常见问题

Verrica Pharmaceuticals Inc的前五大股东是谁？



Verrica Pharmaceuticals Inc 的前五大股东如下：
Manning (Paul B.)持有股份：4.98M，占总股份比例：52.73%。
BKB Growth Investments LLC持有股份：597.61K，占总股份比例：6.33%。
Caligan Partners, LP持有股份：923.91K，占总股份比例：9.78%。
Armistice Capital LLC持有股份：888.13K，占总股份比例：9.40%。
The Vanguard Group, Inc.持有股份：216.83K，占总股份比例：2.30%。